EBITDA: Income before interest, taxes, depreciation and amortization.
Salarius Pharmaceuticals, Inc. (SLRX) had EBITDA of $-0.96M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-0.96M |
|
-- |
|
-- |
|
$0.97M |
|
$-0.97M |
|
$0.01M |
|
$-0.96M |
|
$-0.96M |
|
$-0.96M |
|
$-0.96M |
|
$-0.96M |
|
$-0.96M |
|
$-0.97M |
|
|
EBITDA |
$-0.96M |
0.14M |
|
0.14M |
|
$-6.75 |
|
$-6.75 |
|
| Balance Sheet Financials | |
$1.36M |
|
-- |
|
$0.03M |
|
$1.39M |
|
$2.22M |
|
-- |
|
-- |
|
$2.22M |
|
$-0.83M |
|
$-0.83M |
|
$-0.83M |
|
0.14M |
|
| Cash Flow Statement Financials | |
$-2.04M |
|
-- |
|
$0.40M |
|
$2.43M |
|
$0.79M |
|
$-1.64M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
115.44% |
|
115.44% |
|
-68.77% |
|
115.44% |
|
$-5.85 |
|
$-14.44 |
|
$-14.44 |
|